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_____________________________________________________ 
 
ABSTRACT 
The wastewater generated from pharmaceutical industry generally contain high organic load and 
the treatment is primarily carried out using two major types of biological methods; aerobic and 
anaerobic. However, due to high strength, it is infeasible to treat some pharmaceutical wastewater 
using aerobic biological processes. As an alternative, an anaerobic process is preferred to remove 
high  strength  organic  matter.  Anaerobic  wastewater  treatment  is  considered  as  the  most  cost 
effective solution for organically polluted industrial waste streams. In particular the development of 
high rate systems, in which hydraulic retention times (HRT) are uncoupled from solids retention 
times (SRT), has led to a worldwide acceptance of anaerobic wastewater treatment. In this paper, 
literature on anaerobic digestion, anaerobic reactor technology and existing anaerobic treatment of 
pharmaceutical wastewater are presented. In addition, fate of pharmaceuticals in the environment 
was  also  discussed  in  brief.  A  case  study  of  a  laboratory  investigation  into  the  treatment  of 
pharmaceutical wastewater containing the antibiotic Tylosin in an anaerobic reactor was also given. 
Specifically,  it  was  determined  whether  the  anaerobic  reactor  could  be  used  as  a  pre-treatment 
system at an existing pharmaceutical production plant. The performance of the reactor treating real 
pharmaceutical  wastewater  at  various  organic  loading  rate  (OLR)  was  investigated  and  showed 
efficient substrate removal at low OLRs (0.43 – 1.86 kg COD.m
-3.d
-1) by promoting efficient chemical 
oxygen demand (COD) reduction (70 – 75%). Under these conditions, an average of 95% Tylosin 
reduction  was  achieved  in  the  UASR.  However,  increasing  the  OLRs  to  3.73  kg  COD.m
-3.d
-1  by 
reducing the hydraulic retention time (HRT) (4 – 2 d) reduced the COD removal efficiency (45%). 
Changes in the organic loading affected the treatment performance of the anaerobic reactor, and at 
high  OLRs,  it  was  not  able  to  withstand  the  short  HRT,  probably  due  to  the  complexity  of 
pharmaceutical wastewater. 
 
_____________________________________________________ 
 
Keywords: Anaerobic digestion; antibiotic; pharmaceutical wastewater; tylosin; UASR 
 
 
[I] INTRODUCTION 
 
1.1.  Anaerobic digestion 
 
In the past, aerobic processes were very popular for biological 
treatment  of  wastewater  in  the  1960s.  However,  the  energy 
predicament  in  the  early  1970s  brought  about  a  significant 
change  in  the  methodology  of  wastewater  treatment.  Energy 
preservation in industrial processes became a major concern and 
anaerobic processes rapidly emerged as an acceptable alternative. 
One of the important advantages of anaerobic digestion is the 
energy production during the process in the form of  methane. 
Moreover, when high loading rates are accommodated, the area 
needed for the reactor is small. The sludge production is low, 
when compared to aerobic methods, due to the slow growth rates 
of anaerobic bacteria [1].  
    
Figure–1  illustrates  the  advantage  of  anaerobic  system  in 
relation to aerobic treatment [2]. In aerobic process around 40 – 
50% of biological stabilization take place, with its consequent The IIOAB Journal 
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conversion into CO2. The sludge production and non degraded 
material in aerobic system is around 50  – 60% and 5 – 10%, 
respectively.  However,  in  anaerobic  system  most  of  the 
biodegradable  material  is  converted  into  biogas  (around  70  – 
90%), and only small portion of the organic material converted 
into  sludge  (about  5  –  15%). The  material  not  converted  into 
biogas leaves the reactor as non degraded material (around 10 – 
30%). It is notable that the production of methane gas and the 
very low production of solids is the main advantage of anaerobic 
treatment. 
 
Anaerobic wastewater treatment is considered as the most cost-
effective  solution  for  organically  polluted  industrial  waste 
streams  [3].  Toxic  and  recalcitrant  wastewaters,  that  were 
previously believed not to be suitable for anaerobic processes, 
are  now  effectively  treated.  Accordingly,  effluents  from 
manufacturing operations in the pharmaceutical industry, such as 
antibiotic  formulation,  usually  contain  recalcitrant  compounds. 
The  following  section  discusses  briefly  the  effluent  from 
pharmaceutical industry. 
 
 1.2.  Effluent from pharmaceutical industry 
 
The  pharmaceutical  manufacturing  industry  produces  a  wide 
range of products to be used as human and animal medications. 
Manufacturing  can  be  characterized  by  five  main  processes; 
fermentation,  extraction,  chemical  synthesis,  formulation  and 
packaging [4]. Each of these steps may generate air emissions, 
liquid effluents and solid wastes. Liquid effluents resulting from 
equipment cleaning after batch operation contain toxic organic 
residues.  Their  composition  varies,  depending  on  the  product 
manufactured,  the  materials  used  in  the  process,  and  other 
process  details.  Typically,  pharmaceutical  wastewater  is 
characterized  by  high  COD  concentration,  and  some 
pharmaceutical  wastewaters  can  have  COD  as  high  as  80,000 
mg.L
-1[5].  Pharmaceuticals  pose  potential  risks  to  the  aquatic 
environment such as endocrine disrupting and side effects since 
they initially cause specific biological effects [6, 7]. Furthermore, 
wastewaters  produced  from  antibiotic  manufacture  and 
formulation, generally contain  high levels of  soluble organics, 
many of which are recalcitrant [8]. If these compounds are not 
removed by one-site treatment they will be discharged to sewage 
treatment plants (STPs). This then eventually could disturb the 
biological process and the microbial ecology in the STP and the 
receiving surface waters [6, 7, 9–13].  
 
Widespread  work  into  the  occurrence  and  fate  of 
pharmaceuticals  in  the  environment  has  been  carried  out  in 
recent years [14–20]. The aim of the majority of this work has 
been to identify particularly  persistent substances. In addition, 
the  quantities  in  which  they  occur  in  surface  waters  and 
wastewater effluents and the eventual long-term effects they may 
have  in  the  aquatic  environment.  Essentially,  the  detection  of 
pharmaceuticals such as antibiotics in the environment has raised 
concern  about  potential  human  health  effects.  Pharmaceuticals 
can enter the aquatic environment through the sewage treatment 
systems when they are excreted by people, or if they are disposed 
in the home [21]. They can also enter sewage treatment works or 
watercourses  as  a  result  of  discharges  from  pharmaceutical 
manufacturing plants or medical establishments. The degree of 
discharge from sewage treatment works depends on how they are 
affected by the treatment process.  
 
1.3.  Anaerobic  treatment  of  pharmaceutical      
wastewater   
 
Effluent from pharmaceutical wastewater normally treated using 
flocculation,  flotation,  coagulation,  filtration,  settling,  ion 
exchange, carbon adsorption, detoxification of active ingredients 
by oxidation (using ozone wet air oxidation ultraviolet systems 
or peroxide solutions), and biological treatment (using trickling 
filters,  anaerobic,  activated  sludge,  and  rotating  biological 
contactors).  Although  pharmaceutical  wastewater  may  contain 
refractory  organic  materials  that  cannot  be  readily  degraded, 
biological treatment is still a viable choice for treatment [22, 23]. 
However,  due  to  high  strength,  it  is  infeasible  to  treat  some 
pharmaceutical  wastewater  using  aerobic  biological  processes. 
Instead an anaerobic process is preferred to remove high-strength 
organic  matter.  Recently,  the  anaerobic  treatment  of 
pharmaceutical  wastewater containing antibiotics and synthetic 
drug based effluents has been reported. The detail discussion on 
this can be found below. 
 
Table–1 shows treatment of various pharmaceutical wastewater 
using  anaerobic  processes.  Fox  and  Venkatasubbiah
  [24]  have 
demonstrated the use of anaerobic baffled reactor (ABR) in the 
treatment of high sulphate containing pharmaceutical wastewater 
(Isopropyl Acetate fermentation). These workers found that by 
inserting a sulphide oxidation unit, the COD removal efficiency 
could be increased up to 50% at HRT 1 d.  Massé et al. [25] have 
explored  the  effect  of  antibiotics  on  psychrophilic  anaerobic 
digestion of swine manure slurry in sequencing batch reactors 
(SBRs).  In  their  work,  six  antibiotics,  Tylosin,  Lyncomycin, 
Tetracycline,  Sulphamethazine,  Penicillin  and  Carbadox,  were 
individually  added  to  a  pig  diet.  It  is  concluded  that  only 
Penicillin and Tetracycline had an inhibitory effect on methane 
production. Venkata Mohan et al. [26] have demonstrated the use 
of  anaerobic  suspended  film  contact  reactor  (ASFCR)  in  the 
treatment  of  pharmaceutical  wastewater  from  large  bulk  drug 
manufacturing unit (aromatic and aliphatic organic chemicals). 
The  organic  loading  rates  were  varied  from  0.25  to  2.5  kg 
COD.m
-3.d
-1 and the COD reduction is in the range of 60 to 80% 
with methane content of around 60 - 70%. Nandy and Kaul [5] 
demonstrated  anaerobic  pre-treatment  of  herbal  based 
pharmaceutical  wastewater  (e.g.  herbs,  fruits,  flowers,  roots, 
seeds, etc)  using fixed-film reactor (FFR) and showed 76 – 98% 
COD removal at OLR of 10 kg COD.m
-3.d
-1. However, when the 
OLR  increased  to  48  kg  COD.m
-3.d
-1,  the  COD  removal 
efficiency dropped to 46 – 50%. They also found that the reactor 
did not show destabilization under hydraulic and organic shock 
loadings. 
 
Saravanane  et  al.  [27]  has  demonstrated  that  a  fluidized  bed 
reactor (FBR) under anaerobic conditions could be used to treat 
anti-osmotic drug based pharmaceutical effluent (Acetic acid and 
Ammonia).  It  is  reported  that  COD  reduction  attained  a The IIOAB Journal 
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maximum  value  of  88.5%  using  bioaugmentation  through 
periodic addition of acclimated cells every 2 days with 30 - 73.2 
g  of  cells  (1  to  2.5  g.L
-1  of  reactor  volume)  from  an  off-line 
enricher reactor. Furthermore, they also adventured into studying 
on  bioaugmentation  and  treatment  of  Cephalexin  drug  based 
pharmaceutical  effluent  in  an  up-flow  anaerobic  fluidized  bed 
(UAFB) system [28]. The results showed that bioaugmentation 
improved removal efficiency and reactor stability. Ince et al. [29] 
carried out a study on the performance of an up-flow anaerobic 
filter (UAF) treating a chemical synthesis-based pharmaceutical 
wastewater  (Bacampicilline  and  Sultamicilline  Tosylate)  and 
showed 65% COD removal with methane yield being low at 0.20 
m
3  CH4.kg  CODr
-1.  The  performance  of  a  sequencing  batch 
biofilter (SBB) integrating anaerobic-aerobic conditions in one 
tank  to  treat  a  pharmaceutical  wastewater  (Phenols  and  O-
Nitroaniline)  was  studied  by  Buitron  et  al.  [30].  The  results 
showed that at HRT 8 – 24 h and OLR of 4.6 – 5.7 kg COD.m
-
3.d
-1, a COD removal of 95 – 97% was achieved in the combined 
system.  Anaerobic  treatment  of  pharmaceutical  wastewater 
(Penicillin) containing sulphate (3200 mg.L
-1) was carried out by 
Rodríguez-Martinez  et al. [31] in an UASB and showed 85 - 
90%  COD  and  a  sulphate  removal  of  more  than  90%  were 
achieved at an OLR of 1.5 kg COD.m
-3.d
-1 and HRT of 8.3 d. 
However,  the  performance  of  the  reactor  was  affected  (COD 
removal dropped to 70%) when the loading rate was increased to 
2.09 kg COD.m
-3.d
-1 by reducing the HRT to 7 d. The authors 
suggested  that  the  accumulation  of  sulphides  could  be 
responsible  for  the  reduced  performance.  Anaerobic-aerobic 
treatment  of  pharmaceutical  containing  antibiotics  (Ampicillin 
and  Aureomycin)  was  investigated  by  Zhou  et  al.  [32]  in  an 
anaerobic  baffled  reactor  (ABR)  followed  by  a  biofilm  airlift 
suspension  reactor  (BASR).  The  combined  system  resulted  in 
total  COD  removal  of  97.8%  when  ABR  and  BASR  were 
operated at HRT 2.5 d and 12.5 h, respectively. The Ampicillin 
and Aureomycin removal effiencies were 42.1% and 31.3% in 
the ABR, respectively, but did not show substantial removal (less 
than 10%) in BASR for both antibiotics. More recently, Oktem et 
al. [35] have conducted a study on the performance of a lab-scale 
hybrid  up-flow  anaerobic  sludge  blanket  (UASB)  reactor, 
treating a chemical synthesis-based pharmaceutical wastewater. 
At an OLR of 8 kg COD.m
-3.d
-1, COD reduction of 72% was 
achieved in the reactor system. 
 
1.3.  Treatment of pharmaceutical wastewater- 
a case study 
 
In this section, a case study of the treatment of pharmaceutical 
wastewater  containing  the  antibiotic  Tylosin  in  an  up-flow 
anaerobic stage reactor (UASR) is presented. Stage reactors can 
provide  high  treatment  efficiency  for  recalcitrant  substrates 
because phase separation, which generates separate environments 
for acidogenesis and methanogenesis, also promotes favourable 
conditions for microbial populations involved in the degradation 
of recalcitrant compounds.  
 
Tylosin  is  a  macrolide  antibiotic  produced  by  a  strain  of 
Streptomyces fradiae. It has good anti-bacterial activity against 
most pathogenic gram-positive bacteria, and some gram-negative 
bacteria, vibrio, spirochete, coccidian, etc. It is one of the first-
choice drugs against infections caused by mycoplasma. 
 
[II] MATERIALS AND METHODS 
 
The UASR system [Figure–2] comprise four identical cylindrical Plexiglas 
compartments  (stages),  80  mm  internal  diameter  by  640  mm  height, 
linked in series, was constructed for the present study. The active volume 
of the UASR system was 11 L (4 stages of 2.75 L). The operational set-
up,  flow  diagram  and  the  reactor  design  are  presented  in  Figure–2a. 
Each stage of the reactor had a 3-phase separator baffle, angled at 45
o 
and placed 50 mm below the effluent ports, to prevent floating granules 
from washing out with the effluent [Figure–2b]. The walls of the reactors 
were wrapped with a tubular PVC water-jacket, 15mm internal diameter, 
to maintain the reactor temperature at 37
o C. Peristaltic pumps (Watson 
Marlow 100 series) were used to control the influent feed rate to the first 
stage of the UASR. 
 
The pharmaceutical wastewater had the following characteristics; soluble 
COD,  7000 ± 800 mg.L
-1; soluble BOD5, 3500 ± 500 mg.L
-1; sulphate, 
2500 ± 500 mg.L
-1; Total Kjeldahl Nitrogen (TKN), 364 ± 50 mg.L
-1; pH, 
5.2  – 6.8 and Tylosin concentration, 10 to 220  mg.L
-1. In general, this 
study  was  carried  out  in  four  major  steps:  1)  start-up  of  UASR,  2) 
acclimatisation to pharmaceutical wastewater, 3) increase in OLR (0.43 – 
1.86  kg  COD.m
-3.d
-1)  by  altering  feed  COD  (1700  –  7450  mg.L
-1)  at 
constant HRT (4 d), and 4) increase in OLR (2.48 – 3.73 kg COD.m
-3.d
-1) 
by reducing HRT (4 – 2 d) at constant feed COD (7450 mg.L
-1). Table–2 
shows  the  reactor  operating  conditions  during  investigation  of  OLR  on 
treatment  process.  Supernatant  liquor,  gas  and  sludge  samples  were 
taken separately from each stage for analysis. In addition, gas production 
rate was determined separately for each stage. Sample analysis included 
chemical  oxygen  demand  (COD),  pH,  alkalinity,  total  Kjeldahl  nitrogen 
(TKN),  ammonium  nitrogen  (NH3-N),  suspended  solids  (SS),  volatile 
suspended solids (VSS), all according to Standard Methods [39]. 
 
Tylosin  assay  was  performed  by  HPLC  on  a  20cm  Nucleosil  C18 
analytical  column  eluted  with  60  vols  2  mol.dm
-3  sodium  perchlorate 
(NaClO4)  and  40  vols  of  acetronitrile  (CH3CN).    Tylosin  factors  were 
separated  and  detected  at  280nm.  The  integrated  chromatogram  was 
normalised and the relative percentage of each Tylosin factor reported. 
Comparison of each Tylosin sample chromatogram with that of a Tylosin 
base  reference  standard  chromatogram  confirmed  peak  identity  for 
quantification against a 3-point standard curve.  
 
[III] RESULTS AND DISCUSSION 
 
Figure–3 shows temporal changes in the total COD removal and 
fractional  contribution  by  each  stage  of  the  UASR  treating 
pharmaceutical wastewater. Initial fluctuations were attributed to 
technical problems with the peristaltic feed pump. At a reactor 
OLR  of  1.86  kg  COD.m
-3.d
-1  (HRT  4  d),  the  soluble  COD 
reduction was around 70 - 75%. However, when the OLR was 
increased to 2.48 kg COD.m
-3.d
-1 (by lowering the HRT, since 
the strength of the wastewater was limited) the COD removal 
efficiency  decreased  gradually  until  only  around  45%  soluble 
COD  removal  (average  removal  when  reactor  approached 
steady-state) was observed at an OLR of 3.73 kg COD.m
-3.d
-1.  It 
is  unlikely  that  this  was  caused  by  limitations  in  the  reactor 
design as similar ABR have been shown to be capable of over 
90% COD removal at OLR of more than 10 kg COD.m
-3.d
-1 [40]. The IIOAB Journal 
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However,  pharmaceutical  wastewaters  containing  a  high 
proportion  of  spent  fermentation  broths  have  been  shown  to 
require  long  HRT  for  efficient  treatment  [41],  presumably  on 
account  of  their  complex  organic  carbon  content,  and  this  is 
probably limits the UASR performance at HRT below 4 d.  
 
 
Table: 1. Anaerobic treatment of pharmaceutical wastewater 
 
 
Anaerobic Reactor  Type of Pharmaceutical 
Wastewater 
COD Removal 
(%) 
References 
Fixed bed  Phenol  93  Bajaj et al [ 38] 
Periodic baffled system  Chinese traditional medicine  34 - 84  Liu et al [37 ] 
Hybrid up-flow sludge bed  Phenol, Dibutyl Phthalate, Bromo 
Naphthalene, Carbamazepine, Antipyrine 
65 - 75  Sreekanth et al [36] 
Hybrid up-flow sludge bed  Chemical synthesis  72 – 85  Oktem et al [35] 
Up-flow sludge bed  Antibiotic formulation (sulfamerazine)  68 - 89  Sponza and Demirden [34] 
Sequencing batch  bio-film  Chemical / bulk drugs  51  Venkata Mohan et al [33] 
Baffled system  Antibiotic formulation (Ampicillin, 
Aureomycin) 
77 - 90  Zhou et al  [32] 
Up-flow sludge bed  Antibiotic formulation (Penicillin)  90  Rodriguez-Martinez et al [31] 
Sequencing batch   Phenols and O-Nitroaniline  95 - 97  Buitrón et al [30] 
Up-flow filter  Chemical synthesis  65  Ince et al [29] 
Fluidized bed  Cephalexin drug, anti-osmotic drug  88.5  Saravanane et al [27, 28] 
Fixed-film fixed-bed    Herbal-based   76 – 98  Nandy  and Kaul [5] 
Suspended film contact  Bulk drug (aromatic, aliphatic)  60 – 80  Venkata Mohan et al [26] 
Sequencing batch    Swine manure slurry containing 
antibiotics 
80  Massé et al [25] 
Baffled system  Isopropyl Acetate  50  Fox and Venkatasubbiah [24] 
 
 
 
 
 
                                                    
                                                
 
Fig: 1. Advantage of anaerobic system in relation to aerobic treatment [2]. 
 
The  above  results  are  consistent  with  observations  made  by 
Rodriguez-Martinez  et  al.  [31]  in  an  UASB  treating 
pharmaceutical  wastewater  containing  Penicillin  G  macrolide 
antibiotics, who found that the COD removal efficiency was 90% 
at an OLR of 1.5 kg COD.m
-3.d
-1 and HRT 11 d. However, when 
the OLR was increased to 2.09 kg COD.m
-3.d
-1 by reducing the 
HRT to 7 d, the COD removal efficiency dropped dramatically to 
70%. They also found that an increase in the OLR resulted in the 
accumulation  of  hydrogen  sulphide  (sulphate  in  the  feed  was 
3200 mg.L
-1)  which affected the efficiency of the reactor; the 
presence  of  sulphide  is  known  to  inhibit  the  activity  of 
methanogens [42]. 
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Process 
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Effluent 
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CO2 
(40 – 
50%) 
Sludge 
(50 – 60%) 
Effluent 
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Sludge 
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Table: 2. Summary of reactor operating conditions during investigation of OLR on treatment process         
Brewery (%)* 
wastewater 
Pharmaceutical 
(%)* wastewater 
Mean OLR 
(kg COD.m
-3.d
-1) 
HRT (d)  Mean Feed 
COD (mg.L
-1) 
Day 
50  50  0.43  4.0  1700  1 
40–10  60–90  0.86  4.0  3450  41 
0  100  1.23  4.0  4900  82 
0  100  1.53  4.0  6100  109 
0  100  1.86  4.0  7450  166 
0  100  2.48  3.0  7450  188 
0  100  2.98  2.5  7450  212 
0  100  3.73  2.0  7450  231 
0  100  1.86  4.0  7450  250    _____________________________________________________________________________________   
*proportion based on COD 
 
 
 
 
               
                                     (a)                                                     (b) 
 
Fig: 2. (a) UASR system and flow regime; (b) details of an individual UASR stage  
 
It  is  generally  known  the  application  of  anaerobic  treatment 
process  for  industrial  wastewaters  containing  high  amounts  of 
sulphate has been problematic due to the production of hydrogen 
sulphide. The presence of H2S in anaerobic digesters results from 
the  action  of  sulphate-reducing  bacteria  (SRB)  which  utilise 
sulphate  as  terminal  electron  acceptor  and  compete  with 
acetogens  and  methanogens  for  several  key  substrates  in 
anaerobic  digestion  such  as  propionate,  butyrate,  ethanol  and 
acetate  [43].  Moreover,  SRB  are  generally  expected  to  out-
compete other anaerobes in the presence of excess sulphate [44]. 
The pharmaceutical wastewater used in this study contained high 
amount of sulphate and sulphide production from this sulphate 
was thought to be one of the reasons for the poor performance of 
UASR during the period of high OLR (2.48 – 3.73 kg COD.m
-
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3.d
-1). Speece, [45] has stated that at higher OLR, SRB can out-
compete with methanogens for substrate since hydrogen sulphide 
production  can  be  predominant  over  methane  gas  production. 
Kuscu  and  Sponza,  [46]  have  demonstrated  that  hydrogen 
sulphide  concentrations  in  the  gas  were  increased  from  160 
mg.L
-1 to 195 mg.L
-1 when OLR was increased from 2.1 to 3.16 
kg  COD.m
-3.d
-1  in  an  ABR  treating  sulphate  containing 
wastewater  (p-Nitrophenol).  Consequently,  the  decrease  in 
treatment efficiency in the UASR was probably due to sulphide 
inhibition at higher OLRs (2.48 – 3.73 kg COD.m
-3.d
-1). 
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Fig: 3. Total COD reduction (%) of UASR treating pharmaceutical wastewater and fractional contribution (%) to the total 
COD reduction by each stage at different OLR. 
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Fox  and  Venkatasubbiah  [24]  reported  that  as  influent 
pharmaceutical  wastewater  containing  high  sulphate  was 
increased  to  20%  in  an  ABR,  the  reactor  performance 
deteriorated (COD removal efficiency reduced from 50 to 20%) 
as  the  effluent  sulphide  concentration  increased  to  inhibitory 
levels (more than 200 mg.L
-1). In addition, Nandy and Kaul [5] 
have  demonstrated  that  substrate  removal  efficiency  increases 
with  increase  in  HRT  in  anaerobic  treatment  of  herbal-based 
pharmaceutical  wastewater  using  fixed-bed  reactor.  More 
recently, Zhou et al. [32] reported that when HRT of an ABR 
treating  pharmaceutical  wastewater  containing  antibiotics 
(Ampicillin and Aureomycin) was extended from 1.25 to 2.5 d, 
the COD removal efficiency increased  from 77 to 85%. They 
also observed that the antibiotic removal efficiencies increased 
from 16 to 42% for Ampicillin and 26 to 31% for Aureomycin.  
 
It is evident that stages 2, 3 and 4 showed a relatively minor 
contribution  to  total  COD  removal,  around  50  to  60%  COD 
reduction took place in Stage 1 of the UASR when reactor HRT 
was  set  to  4  d  (i.e.  for  all  reactor  OLR  at  or  below  1.86  kg 
COD.m
-3.d
-1), with less contribution from Stage 2 (around 10 - 
15%), and Stage 3 and 4 accounting for around 5%. This also 
suggests that it was the physiological characteristics of the Stage 
1 effluent that limited further COD degradation in subsequent 
stages of the reactor, rather than excessive OLR, although as the 
pH  was  reduced  in  all  stages  at  the  highest  OLR  (data  not 
presented), there is a possibility that the methanogenic biomass 
in Stages 2, 3 and 4 could also have been affected adversely by 
the  acidic  conditions  generated  in  Stage  1.  Another  possible 
reason could be the sulphide toxicity at higher OLRs in Stage 1 
which inhibited the methanogens in Stage 2, 3 and 4. Moreover, 
the  increase  in  OLR  (by  decreasing  in  HRT)  had  a  greater 
adverse effect on COD degradation efficiency than increases in 
substrate concentration at a fixed HRT. In UASR, the decrease in 
HRT decreased treatment efficiency, especially in Stage 1, and 
since  other  stages  were  not  working  effectively,  the  overall 
treatment efficiency is low. 
 
In  this  study,  Tylosin  concentration  in  the  pharmaceutical 
wastewater  feed  varied  from  10  to  220  mg.L
-1  and  Figure–4 
shows  the  Tylosin  degradation  profile  throughout  the 
experimental  study  in  the  UASR.  Tylosin  removal  efficiency 
fluctuated from 70 – 88% at OLR 1.86 kg COD.m
-3.d
-1, however, 
the removal efficiency remained relatively constant (93 – 99%) 
at OLR 2.48 - 3.73 kg COD.m
-3.d
-1. Similar removal trend was 
also  observed  when  the  reactor  OLR  was  reduced  to  1.86  kg 
COD m
-1 d
-1 [Figure–4], with an average Tylosin concentration 
in  the  treated  wastewater  of  3  mg.L
-1  for  the  all  OLR 
investigated. This confirms that Tylosin was readily degraded in 
the reactor under anaerobic conditions. In contrast to the COD 
removal  profile,  which  showed  reducing  COD  removal 
efficiency with increasing OLR, Tylosin concentration remained 
relatively  constant  in  the  reactor  effluent  throughout  the 
experiment.  These  results  are  consistent  with  the  view  that 
typical  wastewater  concentrations  of  Tylosin  have  a  relatively 
minor influence on the overall COD removal efficiency of UASR 
and  do  not  inhibit  substantially  the  activity  of  methanogenic 
populations.  Some  may  argue  Tylosin  is  hardly  biodegradable 
and could contribute to high COD in the effluent; however, we 
believe,  the  anaerobic  treatment  system  (UASR)  operated  to 
efficiently  remove  most  of  the  general  COD  associated  with 
fermentation  waste  residues  in  the  real  pharmaceutical 
wastewater  containing  Tylosin.  Further  polishing  by  aerobic 
degradation would be viable if tight discharge consent applied 
(i.e. aerobic polishing after anaerobic digestion process is better 
than using aerobic to degrade all COD). 
 
[IV] CONCLUSIONS 
 
Anaerobic  treatment  system  is  a  promising  alternative  for 
pharmaceutical wastewater treatment. Results from the existing 
treatment of pharmaceutical wastewater using anaerobic system  
demonstrates  that  anaerobic  treatment  is  suitable  for  treating 
various type of pharmaceutical wastewater.  The application of 
anaerobic  digestion  to  recalcitrant  streams  such  as  those  from 
pharmaceutical  production  would  provide  significant 
environmental and economic benefits to pharmaceutical industry. 
The UASR system is an appropriate option for pre-treatment of 
wastewaters with a highly complex organic composition, such as 
pharmaceutical wastewater. Results of this study suggest that at a 
reactor OLR of 1.86 kg COD.m
-3.d
-1 (HRT 4 d); the soluble COD 
reduction  was  around  70  -  75%.  Under  these  conditions,  an 
average of 95% Tylosin reduction was achieved in the, indicated 
that this antibiotic could be degraded efficiently in the anaerobic 
reactor system. However, when the OLR was increased to 2.48 - 
3.73 kg COD.m
-3.d
-1, by lowering the HRT, the COD removal 
efficiency decreased to 45%. Whilst COD degradation efficiency 
might be affected by the complexity and variability of the real 
pharmaceutical wastewater, long HRT in the UASR can lessen 
these effects. 
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